ArticleCureus2025
Effect of Topical Travoprost 0.004% Drops on Central Corneal Thickness in Patients With Primary Open-Angle Glaucoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Glaucoma refers to a spectrum of progressive optic neuropathies that damage the retinal ganglion cells and retinal nerve fiber layer, resulting in characteristic changes in the optic nerve head. It is typically associated with intraocular pressure (IOP)-related damage to the optic nerve head. Recent studies have indicated that reduced central corneal thickness (CCT) is a significant risk factor for open-angle glaucoma. Some studies have also documented a notable reduction in CCT in glaucomatous eyes treated with prostaglandin F2α. We aimed to determine the frequency of decreased CCT with topical travoprost 0.004% drops in patients with primary open-angle glaucoma. Materials and methods A descriptive case series of primary open-angle glaucoma patients was performed in the Department of Ophthalmology, Khyber Teaching Hospital, Peshawar, Pakistan, from November 1, 2021, to May 1, 2022. A total of 117 patients of both genders with primary open-angle glaucoma were included in the study. All patients were prescribed topical travoprost 0.004% once daily in the evening in one or both eyes as first-line medication. All patients were followed, and CCT was measured after 10 weeks using ultrasound pachymetry, and CCT was noted. Data was analyzed using SPSS Statistics version 22 (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp.). Decreased CCT was stratified by age, gender, and baseline CCT. The post-stratification chi-square test was applied, and a p-value of <0.05 was considered statistically significant. Results In this study, 63 (53.8%) participants were male and 54 (46.2%) were female. The age range included in the study was from 18 to 70 years, with a mean age of 56.794 ± 7.06 years and a mean baseline CCT of 542.059 ± 7.25 µm. Decreased CCT was observed in seven (6%) patients. Conclusions Decreased CCT (30 µm or more) was observed in seven (6%) patients. Early CCT reduction with travoprost is usually subclinical, with only 6% of eyes showing ≥30 µm decrease. Although generally mild, such changes may influence IOP readings and glaucoma management, warranting further long-term study of prostaglandin effects on the cornea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.